Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 793-797

  He, Zheng ^a   Wu, Hui ^a   Jiao, Yanli ^a   Zheng, Jun ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Aggressiveness; CD55; CD97; Pancreatic cancer; Prognosis

Indexed keywords

CD97 ANTIGEN; DECAY ACCELERATING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATHOLOGY; PROTEIN EXPRESSION;

EID: 84918777242     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2751     Document Type: Article

References (24)

1. 1. Ma C, Jiang YX, Liu SZ, et al: Trend and prediction on the incidence of pancreatic cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi 34: 160-163, 2013 (In Chinese).
2. Ji BT, Silverman DT, Dosemeci M, et al: Occupation and pancreatic cancer risk in Shanghai, China. Am J Ind Med 35: 76-81, 1999.
3. Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin 63: 318-348, 2013.
4. Hamann J, Vogel B, van Schijndel GM and van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184: 1185-1189, 1996.
5. McKnight AJ and Gordon S: The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol 63: 271-280, 1998.
6. Wobus M, Vogel B, Schmucking E, Hamann J and Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer 112: 815-822, 2004.
7. Lin HH, Stacey M, Saxby C, et al: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 276: 24160-24169, 2001.
8. Han SL, Xu C, Wu XL, et al: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis 25: 695-702, 2010.
9. Mustafa T, Eckert A, Klonisch T, et al: Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 14: 108-119, 2005.
10. Abbott RJ, Spendlove I, Roversi P, et al: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem 282: 22023-22032, 2007.
11. Hamann J, Stortelers C, Kiss-Toth E, et al: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28: 1701-1707, 1998.
12. Hamann J, Wishaupt JO, van Lier RA, et al: Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 42: 650-658, 1999.
13. Qian YM, Haino M, Kelly K and Song WC: Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98: 303-311, 1999.
14. Karpus ON, Veninga H, Hoek RM, et al: Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55. J Immunol 190: 3740-3748, 2013.
15. Edge SB, Byrd DR, Compton CC, et al (eds): Exocrine and endocrine pancreas. In: AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, pp 241-249, 2010.
16. Tempero MA, Behrman S, Ben-Josef E, et al: Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 3: 598-626, 2005.
17. Barton MK: Thromboembolism is common and influences prognosis in patients with pancreatic cancer, study reports. CA Cancer J Clin: Jan 18, 2012 (Epub ahead of print).
18. Yang GY, Wagner TD, Fuss M and Thomas CJ: Multimodality approaches for pancreatic cancer. CA Cancer J Clin 55: 352-367, 2005.
19. Mustafa T, Klonisch T, Hombach-Klonisch S, et al: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 24: 285-294, 2004.
20. Sutavani RV, Bradley RG, Ramage JM, et al: CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol 191: 5895-5903, 2013.
21. Durrant LG, Chapman MA, Buckley DJ, et al: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52: 638-642, 2003.
22. Liu Y, Chen L, Peng SY, Chen ZX and Hoang-Vu C: Role of CD97 (stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B 6: 913-918, 2005.
23. Loberg RD, Wojno KJ, Day LL and Pienta KJ: Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 66: 1321-1326, 2005.
24. Wu J, Lei L, Wang S, Gu D and Zhang J: Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol 2012: 587672, 2012.